studies with biomarkers as a primary end point has not significantly increased in the last 10 years; however, preclinical studies are more likely to use AKI biomarkers as a primary end point compared with clinical studies [odds ratio 2.31 (95% confidence interval 1.17-4.59); P ¼ 0.016]. Conclusion. Differences between clinical and preclinical studies are evident and may affect the translation of preclinical findings in the clinical setting.
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I N T R O D U C T I O N
Acute kidney injury (AKI) is a common and serious clinical condition with an overall incidence estimated to be $ 2-3/1000 population, a rate very similar to that for myocardial infarction [1] . Critically ill patients who develop AKI have worse outcomes, such as higher mortality, prolonged hospitalization and increased risk for progression to cardiovascular events and chronic kidney disease (CKD) [2, 3] . Even small increases in serum creatinine may greatly impact long-term outcomes [4] . Despite intense investigation, therapeutic interventions to limit the development and impact of AKI have not been successful. This may be related, at least in part, to the difficulties in identifying patients who are at high risk for AKI or to detect kidney damage early when it may be more treatable [5] . Current AKI definitions are based on changes in serum creatinine and urine output-the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) criteria [6] for example. However, serum creatinine is a late indicator of AKI and is often influenced by factors such as age, muscle mass, protein intake and gender [7] . Urine output may be more sensitive but is less specific for AKI unless severely decreased. Over the last decade, there has been extensive research for novel biomarkers of kidney injury for timely identification of AKI, to allow appropriate interventions and to improve outcomes [8] . The most promising biomarkers can be separated into different classes: (i) tubular cell enzymes released after renal injury, (ii) inflammatory mediators or cytokines released by kidney-specific cells or by inflammatory cells after damage and (iii) low molecular weight proteins, which either are filtered freely in the glomeruli and not adequately reabsorbed or digested by injured tubular cells or are released by injured tubular cells following acute damage. More recently, cell cycle arrest biomarkers, like tissue inhibitor of metalloproteinase 2 (TIMP-2) and insulin-like growth factorbinding protein 7 (IGFBP7) have been validated as indicators of renal damage and their product can predict the onset of severe AKI within 12 h better than other known biomarkers [9] . AKI biomarkers may help explain the molecular mechanisms of AKI and could perhaps be used as phenotyping tools in clinical practice to identify patients with specific AKI etiologies or to predict long-term outcomes [8, 10] . The adoption of novel AKI biomarkers into clinical practice may depend in part on whether therapies can be directly linked to biomarker signals. As such, it is vital to understand whether these markers are being incorporated into clinical and preclinical studies. The purpose of this systematic review is to evaluate the use of AKI biomarkers in preclinical and clinical studies, analyzing the differences in how these markers were used in different settings.
M A T E R I A L S A N D M E T H O D S

Data source and search strategy
This systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. Two different databases (PubMed and Ovid MEDLINE) were searched for articles without language restriction up to February 2016 through a focused search strategy (Supplementary data, Table S1 ). References from relevant studies published on the same topic were screened to identify additional studies. The search was designed and performed by two authors (M.F. and J.A.K.).
Study selection
We included any clinical and preclinical interventional study in which novel AKI biomarkers were used for enrollment criteria and/or for outcome assessment. Preclinical interventional studies were defined as studies that tested a drug, procedure or other medical treatment using in vivo (animals) or in vitro models (cell culture) before trials were carried out in humans. Clinical interventional studies are identified as prospective studies or randomized clinical trials designed to test the safety and effectiveness of a new drug, device or treatment in humans. Studies were excluded if (i) AKI biomarkers were evaluated as diagnostics, (ii) they did not focus on AKI, (iii) they dealt with AKI but did not report data about AKI biomarkers and (iv) they were not an interventional design. Case reports, reviews, editorials and letters were excluded as well. Study selection was independently performed by two authors (M.F. and G.C.) using the EndNote bibliography manager to screen the citations based on titles and abstracts and then to evaluate the full text of the articles previously screened. Discrepancies in judgment were solved collegially.
Data extraction and synthesis
Data extraction and analysis were performed by two authors (M.F. and J.A.K.). The selected studies were divided into preclinical and clinical and in each study we analyzed the following key questions: (i) Are biomarkers used in the definition of AKI? (ii) Are there differences in the setting in which clinical and preclinical studies were based? (iii) Are biomarkers used as primary or secondary end points in these studies? We also compared studies with similar exposures and/or interventions but with divergent outcomes between the preclinical and clinical setting. From each study, the following information was extracted: first author, year of publication, sample size, population or animal setting, definition of AKI and what biomarker was evaluated and how (primary or secondary end point). We evaluated the proportions of studies that answered these specific questions and the comparison of their proportion between clinical and preclinical studies, using the v 2 test and logistic regression. Statistical analyses were performed using SPSS (version 21; IBM, Armonk, NY, USA).
Search results
The flow diagram of the study selection process is shown in Figure 1 . The primary search revealed 5622 publications from the two databases (22 additional articles were found by searching bibliographies), which were evaluated for eligibility by title and abstract. First, 4996 articles were excluded because of search overlap (n ¼ 2435); because they were case reports, reviews, editorials or letters (n ¼ 1147) or because they did not deal with AKI topics (n ¼ 1017) or AKI biomarkers (n ¼ 397). There were 626 publications evaluated in detail. Among these, 475 were excluded because they were not based on an interventional design. A total of 151 studies were therefore included in this analysis (76 clinical, 75 preclinical studies). The majority of preclinical studies focused on animals [n ¼ 72 (96%)], while only three studies (45) were performed using in vitro models [11] [12] [13] .
Time frame and settings of clinical and preclinical studies
The majority of selected clinical trials or prospective studies were dated after 2007, while only four studies before this date considered AKI biomarkers in their analysis. Conversely, preclinical studies are more equally distributed over time. The settings in which the selected studies are focused varied significantly between clinical and preclinical studies and are summarized in Tables 1 and 2 , respectively. Clinical trials and prospective studies were mainly focused on surgical patients, particularly in patients undergoing cardiac surgery [14] [15] [16] [17] [18] [19] [20] [21] [22] In contrast, animal models of AKI were frequently focused on several models of renal ischemia-reperfusion injury (42.6% of selected preclinical studies) [12, 13, . The number of preclinical studies using AKI models induced by nephrotoxic agents (cisplatin, paraquat, gentamicin, vancomycin, herbicide, anesthetic drugs, ketoprofen and other toxics) is significantly greater than in clinical studies (42.6 versus 7.9%; P < 0.001) [105, 112, 114, . Similarly, a greater proportion of preclinical studies focused on sepsis-associated AKI compared with clinical studies (10.6 versus 2.6%; P ¼ 0.04) [150] [151] [152] [153] [154] [155] [156] [157] . However, relatively few preclinical studies considered AKI biomarkers in the surgical setting (5 versus 39%; P < 0.001) [158, 159] or in contrast-induced models of AKI (2.6 versus 17.1%; P ¼ 0.003) [160, 161] .
Definition of AKI
The definition of AKI was highly variable between interventional studies in the clinical and preclinical setting. As described in Table 3 , 57.8% of clinical studies defined AKI according to international consensus criteria, such as the KDIGO guideline criteria [6] , Risk, Injury, Failure. Loss and End-stage kidney disease (RIFLE) criteria [162] or Acute Kidney Injury Network (AKIN) criteria [163] . A few clinical studies (23.6%) defined AKI by the increment of blood urea nitrogen (BUN) or serum creatinine that did not meet these criteria. The aim of these studies was to evaluate the possible role of these biomarkers in specific settings in which AKI diagnosis was performed using the standard criteria. The use of AKI biomarkers in the definition of renal damage was limited to 19.7% of these studies and neutrophil gelatinase-associated lipocalin (NGAL) was the main biomarker used in these studies to define AKI (11.3%). Balkanay et al.
[32] investigated the positive effect of dexmedotomidine on renal injury in patients after coronary artery bypass graft (CABG): in the early postoperative period, the development of AKI, as determined by measurements of blood NGAL levels (>149 ng/mL), was significant and dose dependent. Sahraei et al.
[55] analyzed the protective effects of N-acetylcysteine alone or in combination with vitamin C to alleviate kidney injury in living donor kidney transplantation by measuring interleukin-18 (IL-18) and NGAL levels: no significant differences in delayed graft function (DGF) or NGAL values were found between the two groups. Coca et al. [14] analyzed the relationship between preoperative angiotensin-converting enzyme inhibitors and angiotensin receptor blocker use and AKI in patients undergoing cardiac surgery. The authors defined AKI as functional (based on changes in serum creatinine) or structural [diagnosed by postoperative levels of four urinary biomarkers of tubular damage, NGAL, IL-18, kidney injury molecule-1 (KIM-1) and livertype fatty acid-binding protein (L-FABP)] and described that across three different levels of drug exposure there was an increase in functional AKI while no differences in structural AKI were found. Yousefshahi et al.
[34] evaluated the effect of hypertonic saline infusion versus normal saline on serum NGAL and cystatin C levels in 40 patients undergoing CABG: in this study, AKI was defined by a > 0.3 mg/dL increase in serum creatinine, by serum cystatin C levels > 1.16 mg/dL, or by a significant increase in serum NGAL (>400 ng/mL). The authors did not describe significant differences in NGAL levels between the hypertonic saline group and the normal saline group. Ejaz et al. [16] defined the effect of rasburicase, uric acid-lowering 
therapy, on the prevention of AKI in patients undergoing cardiovascular surgery: AKI was defined according to AKIN criteria or by the increases in urinary NGAL levels and urinary IL-18. While no differences in serum creatinine were found between the two groups (rasburicase versus placebo), active treatment resulted in less evidence of renal structural damage as shown by urinary NGAL concentrations. Cystatin C, IL-18 and KIM-1 were included in the AKI definition in several clinical studies. Yin et al. [83] described the incidence of contrast-associated AKI, defined as an increase in serum cystatin C concentration of !10% from the baseline value within 72 h after coronary intervention, and the preventive effect of probucol in this setting. Kardaros et al. [71] investigated the impact of shockwave lithotripsy on acute renal damage, considering the variations in NGAL, cystatin C and IL-18 levels before and after the procedure as indicators of AKI. Finally, a clinical trial analyzed the effect of remote ischemic preconditioning in alleviating contrast-induced AKI in patients with moderate CKD, using urinary L-FABP as an AKI indicator [84] .
When considering preclinical interventional studies (Table 4) , we found differences in the definition of AKI compared with that in clinical studies. The majority of preclinical studies, in fact, did not include standard AKI definitions previously reported (KDIGO, RIFLE or AKIN criteria) (9.3 versus 57.8%; P < 0.001 comparing preclinical versus clinical studies) and 80% of these studies defined AKI by an unspecified increment of serum creatinine or BUN [13, 90-93, 97-99, 105, 112- [34] used a cut-off that was much higher (>400 ng/mL).
We also compared preclinical and clinical studies in specific settings; in studies on sepsis (eight preclinical, two clinical), only three preclinical studies included biomarkers in the definition of AKI [150, 152, 154] . Among studies focused on a specific drug exposure (cisplatin-associated AKI; 13 preclinical and 5 clinical), only 3 preclinical studies considered AKI biomarkers in the AKI definition [131, 143, 144] and no clinical study did. Focusing on studies on contrast-associated AKI with the same exposure (iodinated contrast media) and interventions (hydration and N-acetylcysteine for preventing AKI; one preclinical and four clinical), we found that two clinical and one preclinical study addressed this point [75, 76, 160] . Among these studies, focusing on studies that analyzed the same biomarker (urinary NGAL) and with divergent outcomes (one preclinical [160] and two clinical studies [77, 82] ), differences in the definition of AKI are evident (the two clinical studies used serum creatinine and KDIGO criteria to define AKI, while the preclinical study included urinary NGAL).
Overall, the number of studies including biomarkers in the definition of AKI increased in the last 6 years in both the clinical and preclinical setting, reaching 20-30% of the selected studies by year (Figure 2) . The odds of including biomarkers in the definition of AKI in preclinical studies is 2.14 times higher than in clinical studies [95% confidence interval (CI) 1-4.6; P ¼ 0.04], while no significant increase over the years was described.
Use of AKI biomarkers as primary or secondary end points
The incidence of AKI, AKI mortality and recovery at specified time points were often used as primary end points in clinical trials or prospective studies focusing on AKI. In these studies, AKI biomarkers were often included in secondary outcomes (48.6% of selected studies) to test their associations with specific conditions, such as cardiac surgeryassociated AKI and sepsis-induced AKI. Zarbock et al. [22] investigated whether remote ischemic preconditioning reduced the rate and severity of AKI in cardiac surgical patients: the primary end point was the rate of AKI, while secondary end points were need of dialysis, mortality and change in AKI biomarkers. They found that remote ischemic preconditioning significantly reduced AKI incidence as well as ameliorated the increase in NGAL and TIMP-2 Â IGFBP7 after cardiac surgery. Similarly, Gallagher et al.
[31] investigated the effect of remote ischemic preconditioning in 86 patients with AKI undergoing cardiac surgery, evaluating the incidence of AKI as the primary end point and the comparison with several biomarkers of renal injury as the secondary outcome. Tasanarong et al. [20] examined the role of erythropoietin (EPO) in reducing the incidence of cardiac surgeryassociated AKI and evaluated possible reductions in urinary NGAL levels in patients who received the treatment. Prowle et al. [164] tested whether short-term perioperative atorvastatin administration could reduce AKI incidence: the primary outcome was the detection of a limited increase in postoperative serum creatinine after atorvastatin therapy, while secondary outcomes included AKI incidence, changes in urinary NGAL, the need for renal replacement therapy (RRT), length of hospitalization and mortality.
More than half of clinical interventional studies included AKI biomarkers in the primary end point of the study (51.4% of selected studies) ( Table 5 ). Kooiman et al. [77] analyzed KIM-1 and NGAL in patients with CKD enrolled in a trial on hydration regimens to prevent contrast-induced AKI and found that the excretion of these biomarkers was unaffected by contrast medium in patients with and without AKI. DeSeigneux et al. [15] tested the hypothesis that different doses of EPO administered to patients in the intensive care unit after cardiac surgery would reduce the incidence of AKI: the primary outcome was the change in urinary NGAL concentration from baseline and 48 h after EPO administration, while secondary outcomes were changes in traditional renal function markers (serum creatinine). Oh et al. [65] analyzed the effect of high-dose statin in patients hospitalized for acute heart failure: the primary outcome was the change in the level of biomarkers related to inflammation and renal injury (cystatin C). Choi et al. [38] found no significant differences in AKI incidence in 76 patients undergoing valvular heart surgery randomly assigned to either remote ischemic preconditioning or a control group. In this study, the primary end points were A higher percentage of preclinical interventional studies included AKI biomarkers in the primary end point compared with clinical studies (68 versus 51.4%; P ¼ 0.03) (Table 6) . Recently, Kim et al. [120] investigated the role of urinary Klotho and NGAL for differentiating pre renal (volume-depleted model) and intrinsic AKI (obtained by injections of cisplatin) in rats and showed a significant reduction of urinary Klotho in pre renal AKI and no differences in NGAL levels between the two groups. Wang et al. [151] analyzed the different expressions of NGAL and other pro-inflammatory cytokines (IL-6, TNF-a) between septic (obtained by cecal perforation) and nonseptic AKI in 17 pigs. Pawar et al. [136] determined that NGAL expression in renal tissue, as well as urinary levels, was significantly higher in mice with nephrotoxic nephritis as compared with control mice and a tight correlation was observed between these levels and renal histopathology.
We also compared preclinical and clinical studies in specific settings: comparing studies on sepsis (eight preclinical and two clinical studies), the majority of preclinical studies (87.5%) used biomarkers as the primary end point [150] [151] [152] [154] [155] [156] [157] , while the two clinical studies used them as the secondary end point [56, 57] . In 18 studies on cisplatin-associated AKI (13 preclinical and 5 clinical), 11 preclinical [105, 112, 114, 120, 121, 128, 130, 131, 133, 143, 144] and all the clinical studies [44-47, 49] used AKI biomarkers as the primary end point. Conversely, among five studies focusing on contrast-associated AKI with the same exposure and specific strategy to prevent AKI (hydration and Nacetylcysteine; one preclinical and four clinical), one preclinical [160] and three clinical studies [75, 77, 82] used the biomarkers as the primary end point. Considering studies that analyzed the same biomarker (urinary NGAL), but with divergent outcomes (one preclinical and two clinical studies [77, 82] ), the three studies used the biomarker as the primary end point.
Overall, there was not an increasing trend in the number of studies using AKI biomarkers as the primary end point in the last 10 years and the percentage of these studies has ranged from 20 to 55.6% of the selected studies by year (Figure 3) . Preclinical studies are more likely to use biomarkers as the primary end point compared with clinical studies [odds ratio 2.31 (95% CI 1.17-4.59); P ¼ 0.016].
D I S C U S S I O N
Failure to translate basic discoveries in AKI pathophysiology into clinical treatments has been a major impediment to [164, 165] . Differences between clinical and preclinical studies may represent one of the most important barriers to successful translation into clinical practice. With the present study, we analyzed the differences between clinical and preclinical studies on AKI biomarkers based on the setting and the etiologies on which they are focused, the inclusion of biomarkers in the definition of AKI and their use as primary or secondary end points in interventional studies.
There is an important disconnect between studies concerning the setting in which they evaluated AKI. A significant percentage of clinical studies analyzed AKI in patients undergoing cardiothoracic surgery or with contrast-associated AKI, while ischemia-reperfusion injury and drug-associated AKI predominating in preclinical studies. These differences may help explain the limited reproducibility of results obtained by experimental analyses in clinical studies since AKI in the clinical setting is related to multiple conditions and may involve different pathogenic features. A host of cellular and molecular pathways involving injury, regeneration and repair have been implicated [164, 166, 167] . To be useful, a model organism must recapitulate the clinical and molecular (subclinical) features of the disease in question. For AKI, these features are limited to changes in function (e.g. 
increased serum creatinine) and evidence of damage (e.g. changes in biomarkers). Histologic changes are also relevant, but to a far lesser extent, because renal tissue is rarely obtained from humans with AKI.
As previously described [7, 8, 10] , the AKI definition was an important source of heterogeneity. In our analysis, only $20% of all clinical interventional studies actually included novel biomarkers of renal injury, while about one-third of preclinical studies used them. Many studies deviated from standard criteria to define AKI and one of the most frequent deviations, was to ignore the urinary output criteria altogether. In most studies, particularly in the preclinical setting, AKI was based only on serum creatinine elevations, despite this marker's well-known deficiencies. Differences in biomarker results and 'AKI' may be explained in part by the lack of sensitivity for serum creatinine. Indeed, false positives (true tubular damage, but negative serum creatinine) or false negatives (no significant tubular injury, but an increase in serum creatinine related to prerenal AKI or due to other confounding variables) were observed. In such scenarios, it will be important for future studies to investigate 
clinical outcomes (including long-term outcomes) for patients who appear to develop subclinical AKI (biomarker positive but serum creatinine negative). AKI diagnosis and staging based on standard criteria developed for humans (e.g. RIFLE) have been applied to both laboratory animals [112, 153] and veterinary patients [100, 151] . NGAL and KIM-1 were first identified in animals and then validated in humans and, recently, the cell cycle arrest biomarker TIMP-2 Â IGFBP7, the only FDA-approved biomarker for AKI, was validated in animals [168] . Thus we believe that AKI definitions and biomarkers can be used across species. The question is whether they have been and to what extent. Overall, only a limited number of studies have investigated biomarkers for AKI severity and long-term outcomes (renal recovery, progression to CKI, cardiovascular events and mortality), mainly as secondary end points [43, 67, 68, 122, 164] . Few studies examining AKI biomarkers have suggested their potential role to distinguish patients at risk of severe AKI requiring RRT and the available data are not sufficient to conclude that biomarkers should be used for the clinical decision to begin RRT. For this reason, the identification of new biomarkers or novel ways to use known biomarkers, such as robust clinical prediction models that integrate biomarkers and clinical variables, need to be developed to increase their use in clinical practice. A critical need is to improve the design of preclinical and clinical studies in AKI settings to identify potential therapeutic targets and translate findings in preclinical studies in humans for the prevention and treatment of AKI. Future directions in preclinical research should aim to improve animal models to better reproduce human AKI and its characteristics. Table 7 summarizes the main findings of the present study, as well as recommendations for future AKI biomarkers research.
In conclusion, this study highlights the main differences in terms of settings and the inclusion of novel biomarkers in the definition of AKI and in the assessment of outcomes between clinical and preclinical interventional studies focused on AKI biomarkers. Overcoming this disconnect could be fundamental to improving our understanding of the pathophysiology of AKI and the potential therapeutic options. 
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